Abstracts tagged "pulmonary"

Abstract Number: 1734 • ACR Convergence 2023
Serum PDGF-BB Levels Correlate with Lung Fibrosis in Mice Injected with Malondialdehyde-Acetaldehyde and/or Citrulline Modified Vimentin
Nozima Aripova¹, Michael Duryee¹, Carlos Hunter¹, Amy Nelson¹, Breanna Butler¹, Jill Poole¹, Bryant England¹, Geoffrey Thiele¹ and Ted R Mikuls², ¹University of Nebraska Medical Center, Omaha, NE, ²Division of Rheumatology and Immunology, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Pulmonary manifestations of rheumatoid arthritis (RA), such as interstitial lung disease (RA-ILD), are a major contributor to morbidity and mortality. The mechanism of pulmonary…
Abstract Number: 1282 • ACR Convergence 2023
Proteomic Signature in Peripheral Blood and Sputum in Rheumatoid Arthritis Patients with and Without Lung Involvement
Meliha Kapetanovic¹, Olivia Olsson², Jon Einarsson¹, Morteza Najibi³ and Ellen Tufvesson⁴, ¹Lund University and Skåne University Hospital, Lund, Sweden, ²Lund University, Faculty of Medicine, Lund, Sweden, ³Lund University, Institution for clinical sciences, section for rheumatology Lund, Lund, Sweden, ⁴Lund University, Institution for clinical scienses, section for lung medicine and allergy, Lund, Sweden
Background/Purpose: Rheumatoid arthritis (RA) related lung manifestations have a significantly impact the morbidity and mortality. Male gender and RF/ACPA positivity are known risk factors but…
Abstract Number: 1742 • ACR Convergence 2023
Sputum Citrullinated Proteins and Sputum Anti-Cit-S100A8/A9 IgG Antibodies Are Increased in Serum Anti-CCP-IgG Positive Individuals Who Developed RA
Rachna Talluri¹, Sudeshna Sen², Timothy Wilson³, Adam Savage⁴, Mark Gillespie⁴, Tom Bumol⁴, Marie Feser¹, Jill Norri⁵, Michael Holer¹, kevin Deane¹, Paul Thompson² and Kristen Demoruelle¹, ¹University of Colorado Anschutz Medical Campus, Aurora, CO, ²University of Massachusetts Chan Medical School, Worcester, MA, ³Thomas Jefferson University, Philadelphia, PA, ⁴Allen Institute for Immunology, Seattle, WA, ⁵Colorado School of Public Health, Denver, CO
Background/Purpose: The presence of anti-CCP-IgG in the blood identifies individuals who are "at-risk" of developing RA. Our group has reported that in a cohort of…
Abstract Number: 1298 • ACR Convergence 2023
Risk Factors Associated with Venous Thromboembolism in Rheumatoid Arthritis in Clinical Practice
Fiona Oudart¹, Marion THOMAS², Alice Combier³, Anna Molto², Yannick ALLANORE⁴ and Jérôme Avouac⁵, ¹Université Paris Cité, Paris, France, ²HOPITAL COCHIN AP-HP, Service de Rhumatologie, Paris, France, ³APHP / Cochin Hospital, Paris, France, ⁴Université Paris Cité, Paris, France, ⁵Service de Rhumatologie, Hôpital Cochin, AP-HP.Centre – Université Paris Cité, Paris, France
Background/Purpose: Increased risk of venous thromboembolism (VTE) has been reported in rheumatoid arthritis (RA) compared to the general population. However, factors associated with the risk…
Abstract Number: 1763 • ACR Convergence 2023
Asthma Severity Is Associated Increased Serum Anti-cyclic Antibody Level at Baseline and in Increase During Longitudinal Follow-up
Drayton Rorah¹, Linh Ngo², Mario Castro², Kristen Demoruelle³ and Scott Matson⁴, ¹University of Kansas Medical Center, Kansas City, KS, ²University of Kansas School of Medicine, Kansas City, KS, ³University of Colorado Anschutz Medical Campus, Aurora, CO, ⁴University of Kansas School of Medicine, Kansas City, MO
Background/Purpose: The lung airways have been implicated in the pathogenesis of RA. RA-associated autoantibodies, including anti-cyclic citrullinated peptide (anti-CCP) antibodies are found to be generated…
Abstract Number: 1377 • ACR Convergence 2023
Characterization of Pulmonary Manifestations of Sjögren Syndrome: A Multicenter Retrospective Study
Loïc Meudec¹, Cindy Marques², Pierre-Antoine Juge³, Robin Dhote⁴, Anne-Laure Fauchais⁵, Emanuelle Dernis⁶, Olivier Vittecoq⁷, Alain SARAUX⁸, Jacques-Eric Gottenberg⁹, Eric Hachulla¹⁰, Véronique Le Guern¹¹, Philippe Dieudé¹², Marie-Pierre Debray¹³, Antoine Beurnier¹⁴, Raphaele Seror¹⁵, Xavier Mariette¹⁶ and Gaetane Nocturne¹⁷, ¹CHU Kremlin-Bicêtre, Rheumatology, Le Kremlin-Bicêtre, France, ²CHU Pitié Salpétrière, Internal Medicine 1, Paris, France, ³Division of Rheumatology, Inflammation, and Immunity Brigham & Women’s Hospital, Boston, MA, ⁴Department of Internal Medicine, Centre Hospitalier Avicenne, Bobigny, France, ⁵Dupuytren Hospital, Limoges, France, ⁶CH Le Mans, Le Mans, France, ⁷CHU Rouen, Rheumatology, Rouen, France, ⁸CHU Brest, Brest, France, ⁹Rheumatology Department, Strasbourg University Hospital, Strasbourg, France, ¹⁰CHU Lille, Département de Médecine Interne et Immunologie Clinique, Centre de Référence des Maladies Auto-immunes Systémiques Rares du Nord et Nord-Ouest de France (CeRAINO), Lille, France, ¹¹APHP Hôpital Cochin, Paris, France, ¹²Assistance Publique-Hôpitaux de Paris, Bichat-Claude Bernard University Hospital, INSERM UMR1152, University de Paris Cité, Department of Rheumatology, Paris, France, ¹³CHU Bichat, Radiology, Paris, France, ¹⁴CHU Kremlin-Bicêtre, Functional Explorations, Le Kremlin-Bicêtre, France, ¹⁵University Hospital Paris Saclay, Le Kremlin-Bicêtre, France, ¹⁶Université Paris-Saclay, Le Kremlin-Bicêtre, France, ¹⁷APHP, Le Kremlin-Bicêtre, France
Background/Purpose: Sjögren disease (Sjo) is a systemic immune-related disease with pulmonary manifestations occurring in up to 16% of patients [1], including interstitial lung disease (SS-ILD)…
Abstract Number: 1821 • ACR Convergence 2023
The “Weekend Effect” and Rheumatological Association in Patients with Diffuse Alveolar Haemorrhage
Shobhit Piplani¹, Shreya Gulati², Vladimir Jelic¹, Asad Ahmed³, Sung Mi Yoon¹, Donclair Brown¹, Miroslav Radulovic¹ and Beverly Johnson⁴, ¹Jacobi Medical Center/North Central Bronx, Albert Einstein College of Medicine, NYC Health and Hospitals, Bronx, NY, ²Jawahar lal Nehru Medical College, New York, NY, ³SUNY Downstate, Brooklyn, NY, ⁴Albert Einstein College of Medicine, Jacobi/NCB, New York, NY
Background/Purpose: Diffuse alveolar hemorrhage (DAH) is a life-threatening pulmonary complication commonly associated with autoimmune disorders. Limited treatment options are available for DAH, and time to…
Abstract Number: 0256 • ACR Convergence 2023
Nintedanib in Combination with Immunosuppressive Agents Improves Forced Vital Capacity in Connective Tissue Disease-associated PF-ILD: A Single-center Study
Yusuke Ushio¹, Risa Wakiya², Tomohiro Kameda², Shusaku Nakashima², Hiromi Shimada², Taichi Miyagi³, Koichi Sugihara⁴, Rina Mino⁵, Mao Mizusaki², Kanako Chujo⁶, Ryoko Kagawa⁷, Hayamasa Yamaguchi⁷ and Hiroaki Dobashi², ¹Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa University, Miki, Kita District, Kagawa, Japan, ²Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa University, Kagawa, Japan, ³Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa University, Kidagun, Japan, ⁴Kagawa University, Miki-cho, Kita-gun, Japan, ⁵Kagawa University, Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa, Japan, ⁶Kagawa University, Miki, Kita District, Kagawa, Japan, ⁷Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa University, Miki-cho, Kita-gun, Japan
Background/Purpose: Japanese patients with connective tissue disease (CTD) are more likely to have interstitial lung disease (CTD-ILD) than those in Western countries and many CTD-ILDs…
Abstract Number: 1467 • ACR Convergence 2023
Antiphospholipid Antibodies and the Risk of Diffuse Alveolar Hemorrhage in Patients with Systemic Lupus Erythematosus: A Systematic Review and Meta-Analysis
Mariana Gonzalez-Trevino¹, Jeffrey Yang², Larry J. Prokop³, Gabriel Figueroa-Parra¹ and Ali Duarte-Garcia⁴, ¹Division of Rheumatology, Mayo Clinic, Rochester, MN, ²Department of Internal Medicine, Mayo Clinic, Rochester, MN, ³Mayo Clinic Libraries, Mayo Clinic, Rochester, MN, ⁴Mayo Clinic, Rochester, MN
Background/Purpose: Diffuse alveolar hemorrhage (DAH) is one of the most devastating complications of SLE. The exact pathogenesis leading to DAH in SLE is not well…
Abstract Number: 1926 • ACR Convergence 2023
Use of 18F-FDG PET in Assessing Response to Treatment in Adults with Pulmonary Sarcoidosis: A Systematic Literature Review
Koushan Kouranloo¹, Mathangi Krishnakumar² and Mrinalini Dey³, ¹Rheumatology & Internal Medicine Trainee- Surrey, UK. Education fellow University of Liverpool, Liverpool, United Kingdom, ²Wrexham Maelor Hospital, Wrexham, United Kingdom, ³Queen Elizabeth Hospital, London, United Kingdom; University of Liverpool, Liverpool, United Kingdom
Background/Purpose: Sarcoidosis is a chronic, multisystem, granulomatous disease commonly affecting the lungs. Immunosuppressants, particularly corticosteroids, are the mainstay of treatment. Symptoms, severity and response to…
Abstract Number: 0281 • ACR Convergence 2023
Is There a Decreased Risk of Developing CF Arthropathy in CF Patients Undergoing Treatment That Targets the F508del Mutation?
Kristin Schmiedeberg¹, Anna-Lena Walter¹, Lukas Joos¹, Martin Brutsche¹, Johannes von Kempis² and Andrea Rubbert-Roth¹, ¹Cantonal Hospital St. Gallen, St. Gallen, Switzerland, ²Kantonsspital St. Gallen, Division of rheumatology and immunology, St. Gallen, Switzerland
Background/Purpose: Cystic fibrosis (CF) is characterized by mutations within the CFTR (cystic fibrosis transmembrane conductance regulator) gene that result in a defect of the chloride…
Abstract Number: 1514 • ACR Convergence 2023
Phase I Study to Evaluate the Safety of Allogeneic Bone Marrow Derived Mesenchymal Stem Cells for Interstitial Lung Disease in Patients with Connective Tissue Disorders
Andy Abril¹, Isabel Mira-Avendano², Nisha Durand¹, Hassan Baig¹, augustine Lee¹, Meghan Baer¹ and Abba Zubair¹, ¹Mayo Clinic, Jacksonville, FL, ²University of Texas, Houston, TX
Background/Purpose: Interstitial lung disease (ILD) is a leading cause of morbidity and mortality in connective tissue disorders (CTD) including rheumatoid arthritis, scleroderma and inflammatory myopathies.…
Abstract Number: 1927 • ACR Convergence 2023
Manifestations, Management and Outcomes of Interstitial Lung Disease Associated with Anti-synthetase Syndrome: A Systematic Literature Review
Koushan Kouranloo¹, Mrinalini Dey², Veronica Yioe³, Lisa G Spencer³ and Caroline V Cotton⁴, ¹Rheumatology & Internal Medicine Trainee- Surrey, UK. Education fellow University of Liverpool, Liverpool, United Kingdom, ²Queen Elizabeth Hospital, London, United Kingdom; University of Liverpool, Liverpool, United Kingdom, ³Liverpool Regional Lung Disease Service, Aintree Hospital, Lower Lane, Liverpool, United Kingdom, ⁴Department of rheumatology, Liverpool University NHS Foundation Trust, Liverpool, United Kingdom
Background/Purpose: Anti-synthetase syndrome (ASS) is a chronic autoimmune inflammatory condition, characterized by myositis, interstitial lung disease (ILD), arthritis, Raynaud's phenomenon and mechanic's hands. This systematic…
Abstract Number: 0358 • ACR Convergence 2023
Baseline Clinical Features and Biomarker Profiles of the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Systemic Juvenile Idiopathic Arthritis Associated Lung Disease (SJIA-LD) Cohort
Esraa Eloseily¹, Autumn Clark¹, Min-Lee Chang², MaryEllen Riordan³, alan Russell⁴, Marc Natter⁵, Sherry Thornton⁶, Yukiko Kimura⁷ and Grant Schulert¹, ¹Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Boston Children's Hospital, Boston, MA, ³Hackensack Meridian Health, Hackensack, NJ, ⁴Duke Clinical Research Institute, Duke, NC, ⁵Harvard Medical School, Boston, MA, ⁶Cincinnati Children's Hospital, Cincinnati, OH, ⁷Hackensack Meridian School of Medicine, New York, NY
Background/Purpose: Systemic juvenile idiopathic arthritis (SJIA) associated lung disease (SJIA-LD) is an emerging and life-threatening clinical problem with urgent unmet needs including prevalence, pathogenesis, disease…
Abstract Number: 1522 • ACR Convergence 2023
Treatment of Pulmonary Arterial Hypertension in Patients with Connective Tissue Diseases: A Meta-analysis
Mustafa Erdogan¹, Sinem Nihal Esatoglu², Burcak Kilickiran Avci³ and Gulen Hatemi², ¹Marmara University - Pendik Training and Research Hospital, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, ²Istanbul University-Cerrahpasa, Cerrahpasa Medical School, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, ³Istanbul University-Cerrahpasa, Cerrahpasa Medical School, Department of Cardiology, Istanbul, Turkey
Background/Purpose: Treatment options for pulmonary arterial hypertension (PAH) have expanded in the last two decades. However, evidence for the treatment of connective tissue disease-associated PAH…

« Previous Page
1
…
4
5
6
7
8
…
12
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].